Ulcerative Tuberculosis in a Patient Treated with Adalimumab

Authors

  • Outi Varpuluoma Department of Dermatology and Medical Research Center Oulu, Oulu University Hospital, Oulu, Finland
  • Suvi-Päivikki Sinikumpu PEDEGO Research Unit, University of Oulu, Finland; 2 Department of Dermatology and Medical Research Center Oulu, Oulu University Hospital, Oulu, Finland
  • Päivi Jackson PEDEGO Research Unit, University of Oulu, Finland; 2 Department of Dermatology and Medical Research Center Oulu, Oulu University Hospital, Oulu, Finland
  • Kaisa Tasanen
  • Laura Huilaja PEDEGO Research Unit, University of Oulu, Finland; 2 Department of Dermatology and Medical Research Center Oulu, Oulu University Hospital, Oulu, Finland

DOI:

https://doi.org/10.2340/actadv.v102.1616

Keywords:

TNF alfa inhibitor, tuberculosis

Abstract

Abstract is missing (Short Communication)

Downloads

Download data is not yet available.

References

Flynn JL, Chan J. Immunology of tuberculosis. Ann Rev Immunol 2001; 19: 93-129.

https://doi.org/10.1146/annurev.immunol.19.1.93

van Zyl L, du Plessis J, Viljoen J. Cutaneous tuberculosis overview and current treatment regimens. Tuberculosis 2015; 95: 629-638.

https://doi.org/10.1016/j.tube.2014.12.006

Bravo FG, Gotuzzo E. Cutaneous tuberculosis. Clin Dermatol 2007; 25: 173-180.

https://doi.org/10.1016/j.clindermatol.2006.05.005

Barbagallo J, Tager P, Ingleton R, Hirsch RJ, Weinberg JM. Cutaneous tuberculosis: diagnosis and treatment. Am J Clin Dermatol 2002; 3: 319-328.

https://doi.org/10.2165/00128071-200203050-00004

Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med 2015; 372: 2127-2135.

https://doi.org/10.1056/NEJMra1405427

World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. 2018. Available from: https://apps.who.int/iris/bitstream/handle/10665/260233/9789241550239-eng.pdf.

Gómez-Reino JJ, Carmona L, Rodríguez Valverde V, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-2127.

https://doi.org/10.1002/art.11137

Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005; 52: 1986-1992.

https://doi.org/10.1002/art.21137

Hasan T, Au E, Chen S, Tong A, Wong G. Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines. BMJ Open 2018; 8: e022445.

https://doi.org/10.1136/bmjopen-2018-022445

Habib GS. Systemic effects of intra-articular corticosteroids. Clin Rheumatol 2009; 28: 749-756.

https://doi.org/10.1007/s10067-009-1135-x

Wong SH, Gao Q, Tsoi KKF, Wu WKK, Tam LS, Lee N, et al. Effect of immunosuppressive therapy on interferon γ release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax 2016; 71: 64-72.

https://doi.org/10.1136/thoraxjnl-2015-207811

Pai M, Denkinger CM, Kik S v., Rangaka MX, Zwerling A, Oxlade O, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev 2014; 27: 3-20.

https://doi.org/10.1128/CMR.00034-13

Doan TN, Eisen DP, Rose MT, Slack A, Stearnes G, McBryde ES. Interferon-gamma release assay for the diagnosis of latent tuberculosis infection: a latent-class analysis. PLoS ONE 2017; 12: e0188631.

https://doi.org/10.1371/journal.pone.0188631

Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, et al. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011; 37: 88-99.

https://doi.org/10.1183/09031936.00115110

Downloads

Published

2022-04-27

How to Cite

Varpuluoma, O., Sinikumpu, S.-P., Jackson, P. ., Tasanen, K., & Huilaja, L. (2022). Ulcerative Tuberculosis in a Patient Treated with Adalimumab. Acta Dermato-Venereologica, 102, adv00700. https://doi.org/10.2340/actadv.v102.1616

Issue

Section

Short Communication

Categories